| pubmed-article:1970963 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0018956 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0237753 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C1516698 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:1970963 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:1970963 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1970963 | pubmed:dateCreated | 1990-6-18 | lld:pubmed |
| pubmed-article:1970963 | pubmed:abstractText | We used single high doses of cyclophosphamide (4 g/m2) to produce rebound increases in peripheral blood (PB) stem cells (PBSC) during recovery from myelosuppression, enabling their collection by apheresis for later autotransplantation. Thirty-three courses of cyclophosphamide were given to 30 patients with malignant lymphoma, multiple myeloma, or solid tumors. The neutrophil count was less than 0.5 x 10(9)/liter for a mean of 6.9 days (median 7 days), and fever occurred in 17 of 33 courses. Positive blood cultures occurred in two patients, one of whom died. The mean peak level of PB granulocyte-macrophage colony-forming units (CFU-GM) was 1517 x 10(3)/liter (median 2447 x 10(3)/liter), a 14-fold increase above the mean in normal subjects. The peak occurred at a mean of 16.6 days (median 16 days) after cyclophosphamide, generally coinciding with the time to reach 1.0 x 10(9) neutrophils per liter. Normal or minimally involved bone marrow and a rapid rise in leukocyte count during recovery were independent variables correlated to the peak of the rebound increase in PB CFU-GM levels. Previous chemotherapy and the duration of neutropenia were additional independent variables in the group with peak PB CFU-GM levels of greater than 1000 x 10(3)/liter. The mean total CFU-GM collected after a mean of five aphereses was 43.8 x 10(4)/kg body weight (BW) (median 35.5 x 10(4)/kg BW), significantly correlated with the mononuclear cell yield. We conclude that single 4 g/m2 doses of cyclophosphamide effectively produce high levels of PBSC, particularly but not exclusively in patients with normal or minimally involved bone marrow and who have not had intensive recent chemotherapy. | lld:pubmed |
| pubmed-article:1970963 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1970963 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1970963 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1970963 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1970963 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1970963 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1970963 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1970963 | pubmed:issn | 0301-472X | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:CharlesPP | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:RobertsM MMM | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:DaleB MBM | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:SageR ERE | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:ToL BLB | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:HaylockD NDN | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:DysonP GPG | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:DartG WGW | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:ThorpD LDL | lld:pubmed |
| pubmed-article:1970963 | pubmed:author | pubmed-author:ShepperdK MKM | lld:pubmed |
| pubmed-article:1970963 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1970963 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:1970963 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1970963 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1970963 | pubmed:pagination | 442-7 | lld:pubmed |
| pubmed-article:1970963 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:meshHeading | pubmed-meshheading:1970963-... | lld:pubmed |
| pubmed-article:1970963 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1970963 | pubmed:articleTitle | Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. | lld:pubmed |
| pubmed-article:1970963 | pubmed:affiliation | Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia. | lld:pubmed |
| pubmed-article:1970963 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1970963 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1970963 | lld:pubmed |
